Comparison of topoisomerase I and II expression in primary brain tumor and lung cancer

被引:0
|
作者
Savaraj, N
Xu, R
Landy, H
Lai, SH
Sternau, L
Solomon, J
Wu, CJ
Lampidis, T
Feun, LG
机构
[1] UNIV MIAMI,SCH MED,DEPT NEUROSURG,MIAMI,FL
[2] UNIV MIAMI,SCH MED,DEPT CELL BIOL,MIAMI,FL
[3] UNIV MIAMI,SCH MED,HEMATOL ONCOL SECT,MIAMI,FL
[4] UNIV MIAMI,SCH MED,DEPT MED,MIAMI,FL
关键词
topoisomerase I and II; brain tumor; lung cancer;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Topoisomerase I (TOP I) and II (TOP II) activities and their corresponding levels were analyzed in 27 primary brain tumors and 32 lung cancers (28 NSCLC, 4 SCLC). The TOP I and II activities in primary brain tumors varied from 500-2,000 units/mg and 100-3,000 units/mg respectively. Their corresponding levels varied from <0.01-3.30 (TOP I) and 0.24-8.30 (TOP II) arbitrary units. In lung cancer, the TOP I and II activities ranged from 1,000-4,000 and 500-4,000 units/mg respectively with their levels ranging from 0.30-61.60 and 0.2-14.2 arbitrary units respectively. These parameters were compared in both tumors using the Wilcoxon rank sums test, the difference were statically significance for all four parameters with a p<0.0001 for TOP I and II activities and TOP I levels and p<0.09 for TOP II levels. Using linear regression analysis, there was no correlation between TOP I and II activities and their corresponding levels in primary brain tumor. However, in lung cancer, the relationship between TOP I activities and levels were linear with r(2)=0.2 and p<0.0094, but not for TOP II activity and their levels. There was no relationship between TOP I and TOP II levels in the same tumor for both types of cancer. The future clinical implication of these findings are discussed.
引用
收藏
页码:857 / 861
页数:5
相关论文
共 50 条
  • [21] Expression dynamics and functional implications of DNA topoisomerase IIβ in the brain
    Tsutsui, Kimiko M.
    Sano, Kuniaki
    Hosoya, Osamu
    Tsutsui, Ken
    ANATOMICAL SCIENCE INTERNATIONAL, 2006, 81 (03) : 156 - 163
  • [22] Expression dynamics and functional implications of DNA topoisomerase IIβ in the brain
    Tsutsui K.M.
    Sano K.
    Hosoya O.
    Tsutsui K.
    Anatomical Science International, 2006, 81 (3) : 156 - 163
  • [23] DNA topoisomerase IIα and -β expression in human ovarian cancer
    S Withoff
    A G J van der Zee
    S de Jong
    H Hollema
    E F Smit
    N H Mulder
    E G E de Vries
    British Journal of Cancer, 1999, 79 : 748 - 753
  • [24] DNA topoisomerase IIα and -β expression in human ovarian cancer
    Withoff, S
    van der Zee, AGJ
    de Jong, S
    Hollema, H
    Smit, EF
    Mulder, NH
    de Vries, EGE
    BRITISH JOURNAL OF CANCER, 1999, 79 (5-6) : 748 - 753
  • [25] Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer
    Ando, M
    Eguchi, K
    Shinkai, T
    Tamura, T
    Ohe, Y
    Yamamoto, N
    Kurata, T
    Kasai, T
    Ohmatsu, H
    Kubota, K
    Sekine, I
    Hojo, N
    Matsumoto, T
    Kodama, T
    Kakinuma, R
    Nishiwaki, Y
    Saijo, N
    BRITISH JOURNAL OF CANCER, 1997, 76 (11) : 1494 - 1499
  • [26] EXPRESSION OF TOPOISOMERASE-II-ALPHA AND TOPOISOMERASE-II-BETA IN CHINESE-HAMSTER LUNG-CELLS RESISTANT TO TOPOISOMERASE-II INHIBITORS
    KHELIFA, T
    CASABIANCAPIGNEDE, MR
    RENE, B
    JACQUEMINSABLON, A
    MOLECULAR PHARMACOLOGY, 1994, 46 (02) : 323 - 328
  • [27] Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer
    M Ando
    K Eguchi
    T Shinkai
    T Tamura
    Y Ohe
    N Yamamoto
    T Kurata
    T Kasai
    H Ohmatsu
    K Kubota
    I Sekine
    N Hojo
    T Matsumoto
    T Kodama
    R Kakinuma
    Y Nishiwaki
    N Saijo
    British Journal of Cancer, 1997, 76 : 1494 - 1499
  • [28] Topoisomerase II alpha content and topoisomerase II catalytic activity cannot explain drug sensitivities to topoisomerase II inhibitors in lung cancer cell lines
    Yamazaki, K
    Isobe, H
    Hanada, T
    Betsuyaku, T
    Hasegawa, A
    Hizawa, N
    Ogura, S
    Kawakami, Y
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1997, 39 (03) : 192 - 198
  • [29] MULTIDRUG SENSITIVITY PHENOTYPE OF HUMAN LUNG-CANCER CELLS ASSOCIATED WITH TOPOISOMERASE-II EXPRESSION
    GIACCONE, G
    GAZDAR, AF
    BECK, H
    ZUNINO, F
    CAPRANICO, G
    CANCER RESEARCH, 1992, 52 (07) : 1666 - 1674
  • [30] Expression of DNA topoisomerase I and DNA topoisomerase II-Alpha in testicular seminomas.
    Coleman, LW
    Perkins, SL
    Holden, JA
    Ashwood, ER
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2000, 114 (02) : 298 - 299